Haemonetics (NYSE:HAE) had its price target raised by analysts at Barrington Research from $90.00 to $93.00. They now have an "outperform" rating on the stock.
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics [Yahoo! Finance]
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics
Vivasure Medical Announces Acquisition by Haemonetics Corporation [Yahoo! Finance]
Haemonetics (NYSE:HAE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $88.00 price target on the stock.